CTNND1 was previously identified to bind and stabilize cadherins, further regulating Wnt/β-catenin signaling pathway activity during tumor progression [50, 51], and the CTNND1 mutation was associated with adverse OS in the EA cohort. The gene discussed is CDH17; the disease is neoplasm.